A Study of Decreased Mental Function Associated With HIV

Completed 90 enrolled National Institute of Allergy and Infectious Diseases (NIAID)

Treatment

Summary

The purpose of this study is to compare pictures of the brain of HIV-infected people with memory problems before and after treatment with selegiline. Selegiline is the study drug received through A5090. HIV patients generally develop memory problems late in the disease. This will be examined using noninvasive proton magnetic resonance spectroscopy (1H-MRS). The effect of the drug selegiline on memory problems also will be examined.

Timeline

Start: —
Primary completion: —
Completion: 2005-06

Outcome

Missed primary endpoint

paper Evaluation of the change in NPZ-8, NPZ-6, and cognitive domain scores from baseline to weeks 12 and 24 revealed no significant differences between treatment arms. PMID 19890073 ↗

Publications

Results Schifitto G, Yiannoutsos CT, Ernst T, Navia BA, Nath A, Sacktor N, Anderson C, Marra CM, Clifford DB; ACTG 5114 Team. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009 Dec 8;73(23):1975-81. doi: 10.1212/WNL.0b013e3181c51a48. Epub 2009 Nov 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selegiline	Unknown	3 mg	Other
Subject	Selegiline	Unknown	6 mg	Other